William Anthony Mcbride

US Patent:

RE37710, May 21, 2002

Filed:

May 18, 2000

Appl. No.:

09/572339

Inventors:

William J. McBride - Summit NJ
Habibe Karacay - Matawan NJ
Gary L. Griffiths - Morristown NJ

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

A61K 5100

US Classification:

424 169, 424 111, 424 165, 424 91, 530300, 530328, 530313, 534 10, 534 14

Abstract:

Peptide, derivatives of leutenizing hormone releasing hormone that are capable of binding radionuclides are provided. The peptide derivatives are readily labeled with isotopes of rhenium or technetium, while retaining their ability to tightly bind LHRH receptors. Methods for preparing the labeled peptides and their use in methods of radiodiagnosis and radiotherapy are described.

US Patent:

6576746, Jun 10, 2003

Filed:

Oct 13, 1999

Appl. No.:

09/417109

Inventors:

William J. McBride - Summit NJ
Gary L. Griffiths - Morristown NJ

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C07K 1600

US Classification:

530404, 5303891, 5303898, 5303911, 5303915, 5303917, 530402, 530408, 424 111, 424 165, 424 169, 424 93, 424 9322, 424 9351, 4241931, 4241941, 436 63, 436504, 436512, 435 79, 435188, 435810

Abstract:

A method of producing a diagnostic or therapeutic conjugate of a protein, polypeptide or peptide containing at least one disulfide bond which is necessary to maintain its biological activity, and bearing at least one thiol-containing moiety linked thereto through a hydrazone or hydrazine linkage, is effected by contacting said protein, polypeptide or peptide with a thiol-reactive diagnostic or therapeutic agent, either preformed or generated in situ, to form a stable diagnostic or therapeutic conjugate of the protein, polypeptide or peptide without substantial cleavage of the disulfide bond. Diagnostic and therapeutic conjugates produced using the foregoing method, as well as kits for carrying out the method are provided.

US Patent:

6953675, Oct 11, 2005

Filed:

Nov 4, 1998

Appl. No.:

09/185607

Inventors:

William J. McBride - Summit NJ, US
Zhengxing Qu - Warren NJ, US
Hans Hansen - Mystic Island NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C12P021/04

US Classification:

435 696, 5303871, 435325

Abstract:

A method of making a glycosylated antibody or antibody fragment having a reactive ketone group on the glycosylated site is provided. The method comprises expressing a cell transfected with a vector encoding an antibody having one or more glycosylation sites in a culture medium comprising a ketone derivative of a saccharide or saccharide precursor and, in the case of an antibody fragment, fragmenting the resulting antibody into an antigen-binding antibody fragment. Methods of making immunoconjugates comprising the glycosylated antibodies or antibody fragments also are provided, wherein the antibody or antibody fragment is reacted with an agent comprising a ketone-reactive group. Glycosylated antibodies and antibody fragments having a reactive ketone group on the glycosylated site, immunoconjugates comprising such antibodies and antibody fragments and in vivo targeting methods using such antibodies, antibody fragments and immunoconjugates also are provided.

US Patent:

7011816, Mar 14, 2006

Filed:

Dec 13, 2002

Appl. No.:

10/318401

Inventors:

Gary L. Griffiths - Morristown NJ, US
William J. McBride - Boonton NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

A61K 49/04

US Classification:

424 94, 424 111, 424 149, 424 165, 424 169, 424 91

Abstract:

A method and compositions are described for labeling a targeting agent with Ga-68, in which eluate from an acid-eluted Ge-68/Ga-68 generator is combined with a macrocycle-containing targetable agent. The labeling method and compositions disclosed ensure that a simple elution of gallium-68, taken directly from a generator, can be used without further manipulation to quantitatively label a macrocycle-containing targetable agent. The Ga-68 labeled targeting agent so produced is useful with specific targeting agents, and is most especially useful in a pretargeting method for positron emission tomographic detection.

US Patent:

7045503, May 16, 2006

Filed:

Oct 2, 2000

Appl. No.:

09/676783

Inventors:

William J. McBride - Summit NJ, US
Gary L. Griffiths - Morristown NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

A61K 38/16

US Classification:

514 6, 530300, 530317, 530324, 530333, 530334, 530335, 530336, 424 169, 424 111, 424 157, 424 165, 424 91, 514 2

Abstract:

Novel metal binding ligands are disclosed that may be coupled to peptides for use in methods of diagnosis and therapy. Peptides containing the ligands are produced using a method wherein ligand introduction or cyclization can be conducted at any point during the synthesis of the peptide. Such peptide derivatives are readily labeled with radiometals, such as isotopes of rhenium or technetium, while retaining their ability to tightly bind specific peptide receptors.

US Patent:

7138103, Nov 21, 2006

Filed:

May 17, 2002

Appl. No.:

10/150654

Inventors:

David M. Goldenberg - Mendham NJ, US
Hans J. Hansen - Picayune MS, US
Shui-on Leung - Shatin, HK
William J. McBride - Boonton NJ, US
Zhengxing Qu - Warren NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

A61K 38/04
A61K 39/395
A61K 49/04
A61K 49/06
A61K 51/00

US Classification:

424 169, 424 93, 424 94, 424 941, 424 95, 424 951, 424 952, 424 96, 424 961, 424 941, 4241361, 435188, 514 17, 514 18, 514 10, 514 11, 514 12, 514 13, 514 14, 514 15, 514 16, 530330, 530408, 530409

Abstract:

The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the targetable constructs and bi-specific antibodies or antibody fragments, as well as methods for using them.

US Patent:

7560110, Jul 14, 2009

Filed:

Aug 8, 2005

Appl. No.:

11/198846

Inventors:

David M. Goldenberg - Mendham NJ, US
Hans J. Hansen - Picayune MS, US
William J. McBride - Boonton NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

A61K 39/395

US Classification:

4241331, 424 169, 424 93, 424 94, 424 941, 424 95, 424 951, 424 952, 424 96, 424 961, 4241361

Abstract:

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

US Patent:

7914787, Mar 29, 2011

Filed:

May 29, 2009

Appl. No.:

12/474665

Inventors:

David M. Goldenberg - Mendham NJ, US
Hans J. Hansen - Picayune MS, US
William J. McBride - Boonton NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

A61K 39/395
A61K 38/04
C07K 16/46
C07K 7/00

US Classification:

4241331, 424 153, 424 169, 424 93, 424 94, 424 95, 424 96, 4241361, 514 218, 514 219, 530330, 5303873, 530408, 530409

Abstract:

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.